Journey slips on FDA approval of rosacea therapy
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.
CRUK backs AI-powered, virtual radiotherapy trial projects
Cancer Research UK has provided £5.9 million ($7.7 million) in funding to a project that will explore the use of artificial intelligence in trials of radiotherapy treatments, as well as vir
Disc maps out US filing for porphyria drug bitopertin
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.
NICE backs first ophthalmic bevacizumab for NHS use
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m
Novo puts $285m into monthly GLP-1 based on Ascendis tech
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
EHS&S for Biopharma & Pharma Summit
Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities
Europe’s Largest Industry-Led & Dedicated Gathering for mRNA...
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets,
9th Microbiome Movement Summit Europe
Translating Microbiome R&D into Improved Healthcare Outcomes & Commercial Potential
8th Antigen-Specific Immune Tolerance Drug Development Summi...
Building on 7 years of success, the 8th Antigen-Specific Immune Tolerance Summit is back - the only conference dedicated to advancing curative th
The 8th CAR-TCR Summit Europe: Your European Hub of Next Gen...
Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources.